Attached files
| file | filename |
|---|---|
| EX-10.10 - EX-10.10 - Oric Pharmaceuticals, Inc. | d843476dex1010.htm |
| EX-10.4 - EX-10.4 - Oric Pharmaceuticals, Inc. | d843476dex104.htm |
| EX-10.3 - EX-10.3 - Oric Pharmaceuticals, Inc. | d843476dex103.htm |
| EX-5.1 - EX-5.1 - Oric Pharmaceuticals, Inc. | d843476dex51.htm |
| EX-4.2 - EX-4.2 - Oric Pharmaceuticals, Inc. | d843476dex42.htm |
| EX-3.4 - EX-3.4 - Oric Pharmaceuticals, Inc. | d843476dex34.htm |
| EX-1.1 - EX-1.1 - Oric Pharmaceuticals, Inc. | d843476dex11.htm |
| S-1/A - S-1/A - Oric Pharmaceuticals, Inc. | d843476ds1a.htm |
Exhibit 23.1
When the transaction referred to under the heading “Reverse Stock Split” in note 11 of the notes to the financial statements has been consummated, we will be in a position to render the following consent.
/s/ KPMG LLP
Consent of Independent Registered Public Accounting Firm
The Board of Directors
ORIC Pharmaceuticals, Inc.:
We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.
San Diego, California
April , 2020